A Phase I Trial of Bevacizumab and Temsirolimus in Patients With Advanced Malignancy
The Study Drugs:
Bevacizumab is designed to prevent or slow down the growth of cancer cells by blocking the
growth of blood vessels that supply nutrients necessary for tumor growth.
Temsirolimus is designed to block the growth of cancer cells, which may cause cancer cells
If you are found to be eligible to take part in this study, you will be assigned to a dose
level of bevacizumab and temsirolimus combined, based on when you joined this study. Up to
13 dose levels of the study drug combination will be tested. Three (3) participants will be
enrolled at each dose level. The first group of participants will receive the lowest dose
level. Each new group will receive a higher dose than the group before it, if no
intolerable side effects were seen. This will continue until the highest tolerable dose of
the study drug combination is found.
If you choose to enroll in the expansion group of patients being treated at the highest
tolerable dose of the study drug combination found, you will be required to undergo added
testing, as follows:
- You will have additional blood drawn (about 2 teaspoons each time) during Cycle 1. This
blood will be drawn before you begin taking the study drugs; on Day 1 at about 1, 4, 8,
and 24 hours after the start of your first infusion; at Day 8 of Cycle 1; at Day 15 of
Cycle 1; and at the end of Cycle 1. The blood will be used to see how the study drug
combination acts in the body and to learn its effect on cancer cells.
- You will have 2 tumor biopsies performed. These samples will be used to see how the
study drug combination acts in the body and to learn its effect on cancer cells. These
tumor biopsies will be performed during the screening visit and at the end of Cycle 1.
To perform a tumor biopsy, the affected area is numbed with anesthetic and some or all
of the tumor tissue is removed with a small knife.
- You will have extra imaging scans performed and used to see how the study drug
combination may be affecting blood vessels that supply nutrients and oxygen to cancer.
A DCE-MRI scan will be performed during the screening visit, at 24-48 hours after the
start of Cycle 1, and at the end of Cycle 1. Like a regular MRI scan, the DCE-MRI scan
involves passing part or all of the body into a long, narrow tube scanner that is open
at both ends.
Study Drug Administration:
Bevacizumab and temsirolimus will be given in "cycles." Cycles will be about 21 days long
or longer, depending on any side effects you may experience.
Bevacizumab is given by vein on Day 1 of each cycle. On Day 1 of Cycle 1, you will receive
it over 90 minutes. If you tolerate it well in Cycle 1, you will receive it over 60 minutes
in Cycle 2. If you tolerate it well in Cycle 2, you will receive it over 30 minutes in
Cycle 3. It will continue to be given over 30 minutes in Cycle 4 and further cycles, as
long as you still tolerate it well. Also, if the first dose is well tolerated, you may be
given the remaining doses of Bevacizumab in the doctor's office in or near your hometown.
Temsirolimus is given by vein on Days 1, 8, and 15 of each cycle. During Day 1 of Cycle 1,
you will receive it over 60 minutes. If you tolerate it well on Day 1 of Cycle 1, it will
be given over 30 minutes on Days 8 and 15 of Cycle 1 and over 30 minutes in further cycles,
as long you still tolerate it well. Also, if the first dose is well tolerated, you may be
given the remaining doses of Temsirolimus in the doctor's office in or near your hometown.
You will have a physical exam and blood drawn (about 1 tablespoon each time) for routine
tests once between Days 7 and 14 during Cycle 1. During the rest of the cycles, you will
have a physical exam and blood drawn (about 1 tablespoon each time) for routine tests once
every 3 weeks. The status of the disease will be checked by a CT or MRI scan after every 2
cycles, starting after Cycle 2.
Length of Study Participation:
You may continue to receive additional cycles of the study drugs, unless the cancer gets
worse or intolerable side effects occur. In that case, you will be taken off study.
Once your participation is over in this study, you will receive standard-of-care follow-up
for the disease.
This is an investigational study. Bevacizumab and temsirolimus are commercially available.
Bevacizumab is FDA approved for the treatment of colorectal cancer and a type of lung
cancer. Temsirolimus is FDA approved for the treatment of kidney cancer that has spread.
The combination of bevacizumab and temsirolimus is not FDA approved. At this time, it is
being used in research only.
Up to 183 patients will take part in this study. All will be enrolled at MD Anderson.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Maximum tolerated doses (MTDs) + Dose-limiting toxicities (DLTs)
Continuous assessment throughout and determination of dose-limiting toxicities with 21 Day Cycle
Razelle Kurzrock, MD
M.D. Anderson Cancer Center
United States: Institutional Review Board
|UT MD Anderson Cancer Center||Houston, Texas 77030|